CellCentric
Edit

CellCentric

https://www.cellcentric.com/
Last activity: 24.07.2026
Active
Categories: BioTechDrugDiscoveryHealthcareOncologyTherapeutics
Inobrodib (CCS1477): first-in-class p300/CBP small molecule inhibitor drug, to treat specific cancers.
Followers
628
Mentions
20
Location: United Kingdom
Employees: 11-50
Total raised: $391M
Founded date: 2004
Twitter
LinkedIn
Email

Investors 7

Funding Rounds 4

DateSeriesAmountInvestors
07.05.2026Series D$220MVenrock
19.05.2025Series C$120MForbion
24.07.2023-$25MPfizer Ven...
16.05.2018-$26M-

Mentions in press and media 20

DateTitleDescription
24.07.2026Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 30 June 2026 with key figures for the first three months of the 2026/2027 financial year Widespread strong performance In the first quarter of the 2026/2027 financial year, HBM Healthcare Investments generated a profit of CHF 238 million. Once again, net assets exceeded the CHF 2 billion mark as at 30 June 2026. The net asset ...
11.05.2026CellCentric Secures $220M to Accelerate Myeloma Drug InobrodibCellCentric secured $220 million in Series D funding. This capital fuels pivotal clinical trials for inobrodib. Inobrodib is a novel oral p300/CBP inhibitor. It targets relapsed or refractory multiple myeloma. Phase 2 data demonstrated sign...
07.05.2026CellCentric: $220 Million Series D Raised To Advance Inobrodib Trials For Multiple MyelomaCellCentric announced the completion of an oversubscribed $220 million Series D financing to support pivotal clinical trials of inobrodib, the company’s first-in-class oral p300/CBP inhibitor for the treatment of multiple myeloma. The finan...
06.05.2026CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple MyelomaCellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, today announced the completion of an oversubscribed $220 million Series D financing...
06.05.2026CellCentric raises $220M series D to advance myeloma drug through registration, eyes potential IPOIn the last three years, CellCentric CEO Will West has been on a journey that has transformed how he thinks about the future of his company. He used to be “obsessed with pharma deals,” he told Fierce Biotech. Now, the clinical-stage biotech...
06.05.2026CellCentric Raises $220M to Advance Cancer TherapiesCellCentric has announced its oversubscribed $220m Series D financing, which has just closed. The new cash will enable CellCentric to take Inobrodib into phase III trials, offering hope of the first new treatment for years for thousands of ...
06.05.2026CellCentric Raises $220M in Series D FundingCellCentric, a Cambridge, UK-based clinical-stage biotechnology company, raised $220M in Series D funding. The round was led by Venrock Healthcare Capital Partners, with participation from new and existing investors. The company intends to ...
20.05.2025Cellcentric: $120 Million Raised For Treating Multiple MyelomaCellCentric, a clinical-stage biotechnology company developing inobrodib (a first in class oral cancer drug to treat specific cancers, notably multiple myeloma) announced the completion of a $120 million Series C funding round. The funding ...
19.05.2025Top tech startup funding news for today, May 19, 2025It’s Monday, May 19, 2025. Hope you had a great weekend. We’re back with your daily rundown of the biggest startup funding moves in tech. Today’s deals span everything from cancer-fighting biotech and AI-powered drug discovery to high-speed...
19.05.2025Pfizer-backed CellCentric secures $120M for further myeloma trialsPfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple myeloma drug into pivotal trials. The candidate in question, an oral p300/CBP inhibitor dubbed inobrodib, is currently...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In